Ocular Therapeutix (OCUL) Cash from Financing Activities (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Cash from Financing Activities of $2.6 million for Q2 2026, down 97.36% year-over-year from $97.8 million in Q2 2025, and up 777.89% on a QoQ basis from $294000.0 in Q1 2026.
Ocular Therapeutix (OCUL) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Cash from Financing Activities for 14 years, with the latest figure at $2.6 million in Q2 2026.
- Cash from Financing Activities for Q2 2026 came in at $2.6 million, down 97.36% year-over-year; the trailing twelve-month figure through Jun 2026 was $462.6 million (up 317.97% YoY), and the FY2025 annual result was $561.7 million, up 69.14% from the prior year.
- Cash from Financing Activities advanced to $2.6 million in Q2 2026, from $294000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $449.4 million in Q4 2025 and troughed at $78000.0 in Q1 2023.
- A 5-year average of $59.3 million and a median of $4.2 million in 2024 frame the typical range for Cash from Financing Activities.
- The widest annual swing landed in 2024, when Cash from Financing Activities soared 411724.36%; it then plunged 98.7% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $458000.0 in 2022, then soared by 23517.9% to $108.2 million in 2023, then slumped by 95.83% to $4.5 million in 2024, then surged by 9857.37% to $449.4 million in 2025, then plunged by 99.43% to $2.6 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $2.6 million in Q2 2026, $294000.0 in Q1 2026, and $449.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Jun 30, 2026 | 2.58 Mn |
| Mar 31, 2026 | 294,000.00 |
| Mar 31, 2026 | 294,000.00 |
| Dec 31, 2025 | 449.38 Mn |
| Dec 31, 2025 | 449.38 Mn |
| Sep 30, 2025 | 10.36 Mn |
| Sep 30, 2025 | 10.36 Mn |
| Jun 30, 2025 | 97.81 Mn |
| Jun 30, 2025 | 97.81 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | 321.22 Mn |
| Mar 31, 2024 | 321.22 Mn |